Laurel Danes-Webb
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $980, 4.2 times the $231 reported in 2021. Among family clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$374
- Dexcom, Inc.$286
- AbbVie$266
- Corcept Therapeutics$219
- Lilly USA, LLC$206
- Novo Nordisk$181
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,30598%
- Education$772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $374 |
| Dexcom, Inc. | 13 | $286 |
| AbbVie | 16 | $266 |
| Corcept Therapeutics | 5 | $219 |
| Lilly USA, LLC | 12 | $206 |
| Novo Nordisk | 11 | $181 |
| Sequel Med Tech, LLC | 1 | $139 |
| Merck | 8 | $139 |
| Tandem Diabetes Care, Inc. | 2 | $135 |
| Alkermes, Inc. | 6 | $134 |
| Otsuka America Pharmaceutical, Inc. | 7 | $132 |
| Medtronic | 3 | $129 |
| BETA Bionics, Inc. | 1 | $112 |
| Exact Sciences | 5 | $102 |
| Boston Scientific | 1 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Pfizer | 4 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $56 |
| Astellas Pharma US Inc | 3 | $51 |
| Biohaven Pharmaceuticals, Inc. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| AstraZeneca | 3 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| GSK | 2 | $32 |
| Bayer | 2 | $31 |
| Cequr Corporation | 2 | $28 |
| Amgen | 2 | $25 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Vertex | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| RGH Enterprises LLC | 1 | $16 |
| Qiagen, LLC | 1 | $16 |
| Averitas Pharma Inc. | 1 | $15 |
| Cranial Technologies, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,383 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 47 | $68,047 |
| TradjentaLinagliptin | 45 | $53,251 |
| Victoza 3-PakLiraglutide | 29 | $52,094 |
| XareltoRivaroxaban | 27 | $36,087 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $32,683 |
| OzempicSemaglutide | 25 | $30,509 |
| TrulicityDulaglutide | 18 | $21,117 |
| EliquisApixaban | 19 | $19,374 |
| FarxigaDapagliflozin Propanediol | 17 | $18,891 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $18,061 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $12,898 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $9,494 |
| Novolog FlexpenInsulin Aspart | 20 | $6,993 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $5,693 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 30 | $2,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKAnoro Ellipta, Trelegy Ellipta | $32 | $30,95834 claims |
| Novo NordiskOzempic | $181 | $30,50925 claims |
| Lilly USA, LLCTrulicity | $206 | $21,11718 claims |
| PfizerEliquis | $62 | $19,37419 claims |
| AstraZenecaFarxiga | $40 | $18,89117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Logan
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
- Kirt MunsonToledo$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.